TY - JOUR
T1 - Molecular profiling in the management of hepatocellular carcinoma
AU - Soliman, Nadine
AU - Saharia, Ashish
AU - Abdelrahim, Maen
AU - Connor, Ashton A.
N1 - Funding Information:
A.A.C. is supported by the 2023 ASTS Faculty Development Grant
Publisher Copyright:
© 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Purpose of reviewThe purpose of this review is to both summarize the current knowledge of hepatocellular carcinoma molecular biology and to suggest a framework in which to prospectively translate this knowledge into patient care. This is timely as recent guidelines recommend increased use of these technologies to advance personalized liver cancer care.Recent findingsThe main themes covered here address germline and somatic genetic alterations recently discovered in hepatocellular carcinoma, largely owing to next generation sequencing technologies, and nascent efforts to translate these into contemporary practice.SummaryEarly efforts of translating molecular profiling to hepatocellular carcinoma care demonstrate a growing number of potentially actionable alterations. Still lacking are a consensus on what biomarkers and technologies to adopt, at what scale and cost, and how to integrate them most effectively into care.
AB - Purpose of reviewThe purpose of this review is to both summarize the current knowledge of hepatocellular carcinoma molecular biology and to suggest a framework in which to prospectively translate this knowledge into patient care. This is timely as recent guidelines recommend increased use of these technologies to advance personalized liver cancer care.Recent findingsThe main themes covered here address germline and somatic genetic alterations recently discovered in hepatocellular carcinoma, largely owing to next generation sequencing technologies, and nascent efforts to translate these into contemporary practice.SummaryEarly efforts of translating molecular profiling to hepatocellular carcinoma care demonstrate a growing number of potentially actionable alterations. Still lacking are a consensus on what biomarkers and technologies to adopt, at what scale and cost, and how to integrate them most effectively into care.
KW - hepatocellular carcinoma
KW - molecular profiling
KW - next generation sequencing
KW - personalized medicine
KW - Carcinoma, Hepatocellular/genetics
KW - Humans
KW - High-Throughput Nucleotide Sequencing
KW - Liver Neoplasms/genetics
UR - http://www.scopus.com/inward/record.url?scp=85181530275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181530275&partnerID=8YFLogxK
U2 - 10.1097/MOT.0000000000001124
DO - 10.1097/MOT.0000000000001124
M3 - Review article
C2 - 38038621
AN - SCOPUS:85181530275
SN - 1087-2418
VL - 29
SP - 10
EP - 22
JO - Current opinion in organ transplantation
JF - Current opinion in organ transplantation
IS - 1
ER -